Parvathy S, Hussain I, Karran E H, Turner A J, Hooper N M
School of Biochemistry and Molecular Biology, University of Leeds, U.K.
Biochemistry. 1998 Feb 10;37(6):1680-5. doi: 10.1021/bi972034y.
The 4 kDa beta-amyloid peptide that forms the amyloid fibrils in the brain parenchyma of Alzheimer's disease patients is derived from the larger integral membrane protein, the amyloid precursor protein. In the nonamyloidogenic pathway, alpha-secretase cleaves the amyloid precursor protein within the beta-amyloid domain, releasing an extracellular portion and thereby preventing deposition of the intact amyloidogenic peptide. The release of the amyloid precursor protein from both SH-SY5Y and IMR-32 neuronal cells by alpha-secretase was blocked by batimastat and other related synthetic hydroxamic acid-based zinc metalloprotease inhibitors, but not by the structurally unrelated zinc metalloprotease inhibitors enalaprilat and phosphoramidon. Batimastat inhibited the release of the amyloid precursor protein from both cell lines with an I50 value of 3 microM. Removal of the thienothiomethyl substituent adjacent to the hydroxamic acid moiety or the substitution of the P2' substituent decreased the inhibitory potency of batimastat toward alpha-secretase. In the SH-SY5Y cells, both the basal and the carbachol-stimulated release of the amyloid precursor protein were blocked by batimastat. In contrast, neither the level of full-length amyloid precursor protein nor its cleavage by beta-secretase were inhibited by any of the zinc metalloprotease inhibitors examined. In transfected IMR-32 cells, the release of both the amyloid precursor protein and angiotensin converting enzyme was inhibited by batimastat, marimastat, and BB2116 with I50 values in the low micromolar range, while batimastat and BB2116 inhibited the release of both proteins from HUVECs. The profile of inhibition of alpha-secretase by batimastat and structurally related compounds is identical with that observed with the angiotensin converting enzyme secretase suggesting that the two are closely related zinc metalloproteases.
在阿尔茨海默病患者脑实质中形成淀粉样纤维的4 kDaβ-淀粉样肽源自更大的整合膜蛋白——淀粉样前体蛋白。在非淀粉样生成途径中,α-分泌酶在β-淀粉样结构域内切割淀粉样前体蛋白,释放出细胞外部分,从而防止完整的淀粉样生成肽沉积。α-分泌酶从SH-SY5Y和IMR-32神经元细胞中释放淀粉样前体蛋白的过程被batimastat和其他相关的基于合成异羟肟酸的锌金属蛋白酶抑制剂所阻断,但结构不相关的锌金属蛋白酶抑制剂依那普利拉和磷酰胺素则没有这种作用。Batimastat抑制两种细胞系中淀粉样前体蛋白的释放,其I50值为3μM。去除异羟肟酸部分相邻的噻吩硫甲基取代基或P2'取代基的取代会降低batimastat对α-分泌酶的抑制效力。在SH-SY5Y细胞中,batimastat阻断了淀粉样前体蛋白的基础释放和卡巴胆碱刺激的释放。相比之下,所检测的任何一种锌金属蛋白酶抑制剂都没有抑制全长淀粉样前体蛋白的水平或其被β-分泌酶的切割。在转染的IMR-32细胞中,batimastat、marimastat和BB2116抑制了淀粉样前体蛋白和血管紧张素转换酶的释放,I50值在低微摩尔范围内,而batimastat和BB2116抑制了这两种蛋白从人脐静脉内皮细胞(HUVECs)中的释放。Batimastat和结构相关化合物对α-分泌酶的抑制谱与血管紧张素转换酶分泌酶所观察到的相同,这表明二者是密切相关的锌金属蛋白酶。